The company, which had 806 filings for formulations till March 31, 2015, got approval for 368 of them from various regions worldwide, including 72 from FDA.

The market size for Levofloxacin is estimated to be $28 million (Rs.179 crore) per annum.
The company, which had 806 filings for formulations till March 31, 2015, got approval for 368 of them from various regions worldwide, including 72 from FDA.
The Noida-based integrated drug maker, Jubilant, manufactures and supplies active pharmaceutical ingredients, solid dosage formulations, specialty pharmaceuticals and life science ingredients. The firm also provides services in contract manufacturing and drug discovery solutions to global firms from its 10 production units in India, Canada and the US.
Source-IANS